Bone Marrow Aspiration and Biopsy Medical Services in China

Bone marrow aspiration and biopsy is a diagnostic medical procedure—not a disease—commonly performed in the Department of Hematology to evaluate hematopoietic function, detect blood disorders, and assess bone marrow involvement in systemic conditions. It involves two complementary techniques: aspiration (withdrawal of liquid marrow using a needle) and biopsy (removal of a small core of solid marrow tissue), typically conducted from the posterior iliac crest under local anesthesia. The procedure is essential for diagnosing and staging hematologic malignancies—including leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes—as well as evaluating unexplained cytopenias (anemia, neutropenia, thrombocytopenia), pancytopenia, suspected metastatic cancer, storage disorders (e.g., Gaucher disease), and infections such as tuberculosis or fungal myelitis. Pathogenesis relevance lies not in the procedure itself but in its role to uncover underlying pathophysiologic mechanisms—such as clonal hematopoiesis, marrow infiltration, fibrosis, dysplasia, or hypocellularity—that drive clinical hematologic dysfunction. Epidemiologically, the procedure is routinely indicated across all age groups but most frequently in adults aged 50–75 years, reflecting the higher incidence of hematologic cancers and age-related marrow changes. In China, over 200,000 bone marrow examinations are performed annually in tertiary hospitals, with rising demand driven by improved diagnostics, aging population, and expanded screening for early hematologic neoplasms. Key risk factors prompting referral include persistent fatigue, recurrent infections, unexplained bruising or bleeding, night sweats, weight loss, lymphadenopathy, hepatosplenomegaly, and abnormal peripheral blood counts on routine CBC. While the procedure itself carries low morbidity—minor pain, transient bleeding, or localized infection in <2% of cases—the psychological burden, procedural anxiety, and delays in definitive diagnosis can significantly impair quality of life. Patients often experience anticipatory distress, fear of malignancy, and disruption in daily functioning during the diagnostic odyssey; those with chronic hematologic conditions may face repeated aspirations over time, compounding emotional and physical strain. Importantly, timely and accurate bone marrow evaluation directly informs prognosis, therapeutic selection (e.g., chemotherapy vs. targeted therapy vs. transplant), and monitoring response—making it a cornerstone of precision hematology care.

Bone marrow aspiration and biopsy (BMAB) is a cornerstone diagnostic and staging procedure in hematology, primarily performed to evaluate hematologic malignancies (e.g., acute and chronic leukemias, lymphomas, multiple myeloma), bone marrow failure syndromes (e.g., aplastic anemia, myelodysplastic syndromes), unexplained cytopenias or cytoses, suspected metastatic disease, storage disorders, and infections such as disseminated tuberculosis or histoplasmosis. It is not a therapeutic intervention per se but serves as the critical gateway to accurate diagnosis, risk stratification, treatment selection, and response monitoring. As such, its clinical utility lies in guiding subsequent conservative, pharmacologic, or surgical interventions.

Conservative management refers to non-invasive, supportive, or observation-based strategies employed before, after, or instead of BMAB—depending on clinical context. In patients with mild, stable cytopenias and low suspicion for malignancy, watchful waiting with serial peripheral blood counts and clinical assessment may be appropriate. For those with iron deficiency anemia or vitamin B12/folate deficiency, conservative correction via oral supplementation and dietary counseling obviates the need for BMAB. Similarly, in cases of reactive thrombocytosis or leukocytosis secondary to infection or inflammation, treating the underlying cause—without bone marrow evaluation—is standard. Conservative measures also include transfusion support (packed red blood cells for symptomatic anemia; platelet transfusions for severe thrombocytopenia with bleeding risk), growth factor administration (e.g., erythropoietin for anemia in chronic kidney disease; granulocyte colony-stimulating factor for neutropenia), and infection prophylaxis in immunocompromised patients. These approaches aim to stabilize the patient while diagnostic clarity is pursued.

Medication plays a pivotal role both pre- and post-procedure and, more importantly, as definitive therapy following BMAB-derived diagnoses. Prophylactic antibiotics are generally unnecessary for routine BMAB in immunocompetent patients but may be indicated in neutropenic or immunosuppressed individuals. Analgesics—including acetaminophen or short-term NSAIDs—are routinely administered for localized post-procedural discomfort; opioids are rarely required. Anticoagulant or antiplatelet agents (e.g., warfarin, apixaban, clopidogrel) must be carefully reviewed and often temporarily withheld per institutional protocols to minimize bleeding risk, with bridging strategies considered when clinically warranted. Crucially, BMAB results directly inform pharmacotherapy: acute myeloid leukemia (AML) dictates induction chemotherapy (e.g., cytarabine + idarubicin); chronic myeloid leukemia (CML) mandates tyrosine kinase inhibitors (e.g., imatinib, dasatinib); multiple myeloma guides triplet regimens (e.g., lenalidomide–bortezomib–dexamethasone); and autoimmune cytopenias may require corticosteroids, rituximab, or thrombopoietin receptor agonists. Molecular and cytogenetic findings from the aspirate and biopsy (e.g., FLT3, NPM1, BCR-ABL1, del(5q)) further refine targeted therapy selection and prognostication.

Surgical treatment is not applicable to BMAB itself, as it is a minimally invasive outpatient procedure typically performed under local anesthesia at the posterior iliac crest. However, BMAB frequently informs decisions regarding definitive surgical or procedural interventions. For example, confirmation of lymphoma involvement in marrow may prompt referral for radiation oncology or surgical resection of bulky disease. In patients with high-risk MDS or AML, BMAB is mandatory prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT)—a potentially curative but intensive procedure requiring rigorous donor matching, conditioning regimens, and post-transplant immunosuppression. Additionally, BMAB is essential for evaluating engraftment and detecting minimal residual disease (MRD) post-transplant. Rarely, surgical bone biopsy (e.g., from vertebral body or sternum) may be considered if iliac sampling is inadequate or contraindicated—but this is exceptional and carries higher morbidity.

China offers distinct advantages in the execution and integration of BMAB within comprehensive hematologic care. First, major academic centers—including Peking University People’s Hospital, Shanghai Ruijin Hospital, and Guangzhou Institute of Hematology—maintain standardized, evidence-based BMAB protocols aligned with international guidelines (e.g., EHA, ASH), yet optimized for regional epidemiology (e.g., higher incidence of T-cell lymphomas and EBV-associated HLH). Second, China leads in rapid turnaround times: flow cytometry, cytogenetics, and next-generation sequencing (NGS) panels are routinely completed within 3–5 working days, enabling timely therapeutic decisions. Third, cost-effectiveness is notable—BMAB with ancillary studies costs approximately 30–50% less than in Western countries without compromising quality, facilitated by centralized laboratory networks and government-subsidized diagnostics. Fourth, integration with traditional Chinese medicine (TCM) is unique: many centers offer adjunctive TCM formulations (e.g., Bushen Huoxue decoctions) during recovery to ameliorate fatigue and improve hematopoietic recovery—though these are used as supportive, not替代, therapies and are evidence-informed where possible. Finally, China’s robust digital health infrastructure enables seamless longitudinal tracking of BMAB results alongside electronic health records, facilitating AI-assisted morphologic review and predictive analytics for treatment response.

Recovery following BMAB is typically rapid and uncomplicated. Patients are advised to apply firm pressure to the puncture site for 5–10 minutes immediately post-procedure, followed by a sterile dressing. Mild soreness, bruising, or a small hematoma at the site is expected and usually resolves within 3–5 days; acetaminophen is preferred over NSAIDs for analgesia to avoid platelet inhibition. Patients should avoid heavy lifting (>10 lbs), vigorous exercise, or soaking (e.g., baths, swimming) for 48–72 hours to prevent bleeding or infection. Signs requiring urgent evaluation include persistent or worsening pain beyond 72 hours, fever >38.0°C, expanding hematoma, purulent discharge, or new-onset neurologic symptoms (e.g., radicular pain—rare but concerning for nerve injury). Most patients resume normal activities within 24–48 hours. Importantly, psychological recovery matters: anxiety surrounding BMAB is common, particularly among newly diagnosed patients; therefore, clear pre-procedural counseling, real-time communication of preliminary findings (e.g., morphology report within 24 hours), and timely multidisciplinary follow-up (hematologist, oncology nurse, psychosocial support) significantly improve adherence and outcomes. Nutritional support—including adequate protein, iron, folate, and vitamin B12 intake—is encouraged to optimize marrow reserve, especially in patients with underlying nutritional deficiencies or undergoing cytotoxic therapy. Follow-up BMAB may be scheduled at defined intervals (e.g., day 14 post-induction in AML) to assess treatment response, always guided by disease-specific consensus criteria (e.g., ELN 2022 for AML, IMWG for myeloma). Ultimately, BMAB remains indispensable—not as an endpoint, but as the foundational step that transforms uncertainty into precision hematology.